Morepen Laboratories Limited
NSE: MOREPENLAB · Pharmaceuticals
Snapshot
Unlock Morepen Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Morepen Laboratories is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), branded formulations, and a diverse range of home health diagnostic devices. The company operates across both domestic and international markets, offering products ranging from life-saving drugs to over-the-counter wellness solutions.
Business Model
The company generates revenue through the sale of APIs to global pharmaceutical manufacturers, the distribution of branded formulations, and the retail of medical devices under the Dr. Morepen brand. It further leverages contract manufacturing and brand-sharing partnerships to diversify its income streams.
- Export reach:75 countries
- Incorporation year:1984
Growth Outlook
Growth is driven by the expansion of the point-of-care medical device portfolio and the strengthening of its API manufacturing capabilities. The company continues to focus on its Dr. Morepen brand to capture increasing demand in the Indian over-the-counter healthcare market.
Key Risks
- Regulatory Compliance. The company faces stringent quality control and manufacturing standards from global health authorities, where non-compliance could lead to export bans.
- Market Competition. Intense competition in the generic drug and medical device sectors may exert pressure on profit margins.
- Currency Volatility. As a significant exporter to 75 countries, the company is exposed to fluctuations in foreign exchange rates that can impact profitability.
- Supply Chain Disruptions. Dependence on raw material imports for API manufacturing makes the company vulnerable to global supply chain bottlenecks.
Start your research today
Unlock AI insights, financials, peers and live data on Morepen Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,286 Cr
TTM · consolidated
NET PROFIT
₹189 Cr
TTM · consolidated
EPS
₹3.43
TTM · consolidated
RETURN ON EQUITY
14.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.8%
TTM · consolidated
P/E
31.4×
Q2 FY27 · consolidated
EV/EBITDA
20.0x
Q2 FY27 · consolidated
EBITDA MARGIN
13.2%
TTM · consolidated
NET PROFIT MARGIN
11.9%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Morepen Laboratories LimitedMOREPENLAB | ₹5,901 Cr | 31.4× | 20.00 | 30.2% | 13.2% | 14.6% | 18.8% | +126.3% |
Bliss GVS PharmaBLISSGVS | ₹6,559 Cr | 40.6× | 22.99 | 24.9% | 26.4% | 13.7% | 19.1% | +293.5% |
FDC LimitedFDC | ₹6,205 Cr | 19.8× | 12.28 | 10.2% | 21.9% | 12.3% | 16.1% | -17.3% |
Innova Captab LimitedINNOVACAP | ₹5,729 Cr | 37.2× | 22.58 | 34.5% | 15.4% | 15.0% | 17.4% | +20.5% |
Sun Pharma Advanced Research Company LimitedSPARC | ₹5,682 Cr | 3.6× | 3.80 | 2855.8% | 86.0% | 282.4% | 235.1% | +29.5% |
IOL Chemicals and Pharmaceuticals LimitedIOLCP | ₹5,291 Cr | 26.0× | 14.28 | 26.8% | 13.9% | 11.1% | 14.9% | +94.8% |
As of Q2 FY27
Financials
Morepen Laboratories Limited
NSE: MOREPENLAB · Pharmaceuticals
Snapshot
Unlock Morepen Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Morepen Laboratories is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), branded formulations, and a diverse range of home health diagnostic devices. The company operates across both domestic and international markets, offering products ranging from life-saving drugs to over-the-counter wellness solutions.
Business Model
The company generates revenue through the sale of APIs to global pharmaceutical manufacturers, the distribution of branded formulations, and the retail of medical devices under the Dr. Morepen brand. It further leverages contract manufacturing and brand-sharing partnerships to diversify its income streams.
- Export reach:75 countries
- Incorporation year:1984
Growth Outlook
Growth is driven by the expansion of the point-of-care medical device portfolio and the strengthening of its API manufacturing capabilities. The company continues to focus on its Dr. Morepen brand to capture increasing demand in the Indian over-the-counter healthcare market.
Key Risks
- Regulatory Compliance. The company faces stringent quality control and manufacturing standards from global health authorities, where non-compliance could lead to export bans.
- Market Competition. Intense competition in the generic drug and medical device sectors may exert pressure on profit margins.
- Currency Volatility. As a significant exporter to 75 countries, the company is exposed to fluctuations in foreign exchange rates that can impact profitability.
- Supply Chain Disruptions. Dependence on raw material imports for API manufacturing makes the company vulnerable to global supply chain bottlenecks.
Start your research today
Unlock AI insights, financials, peers and live data on Morepen Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,286 Cr
TTM · consolidated
NET PROFIT
₹189 Cr
TTM · consolidated
EPS
₹3.43
TTM · consolidated
RETURN ON EQUITY
14.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.8%
TTM · consolidated
P/E
31.4x
Q2 FY27 · consolidated
EV/EBITDA
20.0x
Q2 FY27 · consolidated
EBITDA MARGIN
13.2%
TTM · consolidated
NET PROFIT MARGIN
11.9%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27